Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genedx Holdings Corp (WGS)

Genedx Holdings Corp (WGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,699,840
  • Shares Outstanding, K 28,905
  • Annual Sales, $ 305,450 K
  • Annual Income, $ -52,290 K
  • EBIT $ 10 M
  • EBITDA $ 32 M
  • 60-Month Beta 1.99
  • Price/Sales 12.24
  • Price/Cash Flow 126.40
  • Price/Book 12.79

Options Overview Details

View History
  • Implied Volatility 74.99% (-2.22%)
  • Historical Volatility 52.91%
  • IV Percentile 44%
  • IV Rank 20.76%
  • IV High 157.37% on 04/07/25
  • IV Low 53.41% on 08/28/25
  • Expected Move (DTE 2) 3.00 (2.34%)
  • Put/Call Vol Ratio 1.49
  • Today's Volume 1,240
  • Volume Avg (30-Day) 1,875
  • Put/Call OI Ratio 1.13
  • Today's Open Interest 20,098
  • Open Int (30-Day) 30,053
  • Expected Range 125.42 to 131.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.11
  • Number of Estimates 1
  • High Estimate 0.11
  • Low Estimate 0.11
  • Prior Year 0.70
  • Growth Rate Est. (year over year) -84.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
125.46 +1.98%
on 12/30/25
170.87 -25.12%
on 12/02/25
-39.00 (-23.36%)
since 11/28/25
3-Month
107.14 +19.42%
on 10/01/25
170.87 -25.12%
on 12/02/25
+20.21 (+18.75%)
since 09/30/25
52-Week
55.17 +131.91%
on 05/08/25
170.87 -25.12%
on 12/02/25
+51.36 (+67.07%)
since 12/30/24

Most Recent Stories

More News
GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 44th Annual J.P. Morgan Healthcare Conference...

WGS : 128.01 (+0.01%)
JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year

Prestigious recognition underscores the impact of large-scale genomic screening in identifying serious childhood genetic conditions in conjunction with traditional newborn screening

WGS : 128.01 (+0.01%)
GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting

Powered by GeneDx Infinityâ„¢ with unparalleled scale and diversity, GeneDx fuels breakthrough scientific research and delivers the most precise rare disease diagnosis for patients and families

WGS : 128.01 (+0.01%)
GeneDx to Participate in Upcoming Investor Conferences

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: ...

WGS : 128.01 (+0.01%)
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue Accelerated exome and genome volume...

WGS : 128.01 (+0.01%)
GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims

SAN FRANCISCO , Oct. 27, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating...

WGS : 128.01 (+0.01%)
Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

WGS : 128.01 (+0.01%)
GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025

Data from more than 22,000 newborns reinforce GeneDx’s role spearheading the adoption of genomic newborn screening (gNBS) from research to clinical practice

WGS : 128.01 (+0.01%)
GeneDx Granted FDA Breakthrough Device Designation for its ExomeDxâ„¢ and GenomeDxâ„¢ Testing

Designation highlights GeneDx innovation in clinical whole genome and whole exome testing and accelerates the pathway for FDA authorization of these novel diagnostic tests

WGS : 128.01 (+0.01%)
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx

WGS : 128.01 (+0.01%)
ILMN : 130.89 (-1.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

GeneDx Holdings Corp. is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by rare disease data sets. GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in STAMFORD, Conn.

See More

Key Turning Points

3rd Resistance Point 135.35
2nd Resistance Point 132.86
1st Resistance Point 130.43
Last Price 128.01
1st Support Level 125.51
2nd Support Level 123.03
3rd Support Level 120.60

See More

52-Week High 170.87
Last Price 128.01
Fibonacci 61.8% 126.67
Fibonacci 50% 113.02
Fibonacci 38.2% 99.37
52-Week Low 55.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar